Dermatology

Latest News

FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines
FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

April 18th 2025

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria
Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria

April 18th 2025

Study Shows High Rate of Eczema Type Overlap: Daily Dose / image credit: ©New Africa/AdobeStock
Study Shows High Rate of Eczema Type Overlap: Daily Dose

April 11th 2025

Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis / image credit ©Alphyn Biologics
Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis

April 8th 2025

Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care are Persistent and Significant: New Scoping Review / image Peter Lio, MD
Racial and Ethnic Disparities in Pediatric Atopic Dermatitis Prevalence and Care are Persistent and Significant: New Scoping Review

April 7th 2025

Latest CME Events & Activities

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arizona

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

View More

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Wisconsin

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Revolutionizing Atopic Dermatitis (RAD) Conference 2025

June 6-7, 2025

Register Now!

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

July 26, 2025

Register Now!

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

Community Practice Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice?

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

View More

Burst CME: Targeted Therapy for Optimal Psoriasis Management

View More

More News


Site Logo

Role of Anti–SS-A and Anti–SS-B Tests in Sjögren Diagnosis

December 31st 2006

I enjoyed the article by Kenneth H. Fye, MD, "Rheumatic Disease: How to Use theLab in the Workup" (CONSULTANT, March 2004, page 369). However, I foundthe following statement to be misleading: "Anti-SS-A and anti-SS-B determinationsare necessary to rule out Sjgren syndrome in patients with sicca complaints."If the results of these tests are negative, but Sjgren syndrome was initiallysuspected based on the history, labial biopsy is required. Many persons with thisdisease have negative antibody test results.Unfortunately, it often takes years before Sjgren syndrome is correctly diagnosedin most patients. This is usually because a health care provider rules it outbased on negative results of anti-SS-A and anti-SS-B tests.---- Paula Hochberg, ARNPSarasota, FlaYou are correct that negative results of tests foranti-SS-A and anti-SS-B antibodies do not ruleout Sjgren syndrome. Although the majorityof patients with this syndrome have these antibodies,a significant minority do not. If, in thislatter group of patients, Sjgren syndrome is strongly suspectedon clinical grounds, a minor salivary gland biopsyshould be considered. Biopsy is the most specific andsensitive test for Sjgren syndrome. Although a biopsy isnot required to make the diagnosis in every patient, thereare clearly those with negative tests for anti-SS-A andanti-SS-B in whom a biopsy is necessary to confirm suspectedSjgren syndrome. Thus, my statement shouldhave read instead, "Positive anti-SS-A and anti-SS-B determinationssupport a diagnosis of Sjgren syndrome inpatients with sicca complaints."---- Kenneth H. Fye, MDClinical Professor of MedicineRheumatology DivisionUniversity of California, San Francisco,School of Medicine

© 2025 MJH Life Sciences

All rights reserved.